What’s the current market cap for Alcon stock?

Alcon (ALC) has a market cap of $32bn as of June 22, 2026.

What is the P/E ratio for Alcon stock?

The price to earnings (P/E) ratio for Alcon (ALC) stock is 38.79 as of June 22, 2026.

Does Alcon stock pay dividends?

Yes, the Alcon (ALC) stock pays dividends to shareholders. As of June 22, 2026, the dividend rate is $0.23327 and the yield is 0.36%. Alcon has a payout ratio of 20.27% on a trailing twelve-month basis.

When is the next Alcon dividend payment date?

The next Alcon (ALC) dividend payment date is unconfirmed.

What is the beta indicator for Alcon?

Alcon (ALC) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Alcon stock | $ALC Share Price

About Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Ticker

$ALC

Sector

Health

Primary listing

NYSE

Employees

25,000

Headquarters

Geneva, Switzerland

Website

www.alcon.com

Alcon Metrics

BasicAdvanced

$32bn

38.79

$1.67

0.70

$0.23

0.36%

What the Analysts think about Alcon

Analyst ratings (Buy, Hold, Sell) for Alcon stock.

Bulls say / Bears say

First-quarter net sales rose 10% year-over-year to $2.69 billion, driven by 10 new product launches including Clareon TruPlus IOL and Unity, underscoring strong demand for Alcon’s innovation pipeline. (Reuters)

The company raised its full-year 2026 diluted EPS growth guidance to 10–13% (from 9–12%) and authorized a $1.5 billion share repurchase program, signaling confidence in cash flow conversion and shareholder returns. (Reuters)

Alcon cut its assumed U.S. import tariff rate to 10% from 15%, reducing projected tariff expenses by $25 million and demonstrating proactive cost management to support margin resilience. (Reuters)

Q1 net sales of $2.69 billion missed consensus of $2.71 billion as implantables segment revenues remained almost flat amid intensifying competitive pressures. (Reuters)

Alcon’s operating earnings plunged 32% year-over-year to $292 million in Q1 2026, highlighting significant margin compression from elevated R&D spending and tariff-related costs. (Reuters)

Operating margin fell sharply from 15.9% in Q4 2024 to 11.6% in Q4 2025 due to higher product launch investments and tariffs, and growth in China remains vulnerable to volume-based procurement initiatives and economic softness. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 20 Jun 2026.

Alcon Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Alcon Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Alcon News

AllArticlesVideos

Mexican Gold Announces Subscription Receipt Financing and Loan to Alcon Silver in Connection with Arrangement

Newsfile Corp·7 days ago

Swiss eye care firm Alcon's quarterly revenue rises, driven by product launches

Reuters·2 months ago

New Product Launches Drive Alcon's First-Quarter 2026 Growth as Momentum from Unity and Tryptyr Builds

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.